Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAV Study
NCT01202721Phase 3Terminated
- Sponsor
- Hamilton Health Sciences
- Start
- Jun 2011
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atenolol and telmisartan in bicuspid aortic valve disease (BAV) and Aortic Aneurysm (AA) (4 arms), sponsored by Hamilton Health Sciences. Primary endpoint: Change From Baseline in Ascending Aorta Size, as Evaluated by MRI at 3 years. Started Jun 2011; status: terminated.
02
Drugs
atenololtelmisartan
03
Conditions
bicuspid aortic valve disease (BAV)Aortic Aneurysm (AA)
Beyond the preview
Go deeper on NCT01202721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01202721.